Proportion of patients in the ITT population with JIA-ACR70 and JIA-ACR90 response at week 40 by background methotrexate use, background glucocorticoid use and previous biological agent use at baseline*
| Concomitant therapies and previous exposure to biological agent | Response level | Placebo n=81† | Tocilizumab n=82† | ||
|---|---|---|---|---|---|
| Yes | No | Yes | No | ||
| Background methotrexate | JIA-ACR70 | 30/64 (46.9) | 4/17 (23.5) | 45/67 (67.2) | 8/15 (53.3) |
| JIA-ACR90 | 18/64 (28.1) | 1/17 (5.9) | 32/67 (47.8) | 5/15 (33.3) | |
| Background glucocorticoid | JIA-ACR70 | 14/38 (36.8) | 20/43 (46.5) | 23/33 (69.7) | 30/49 (61.2) |
| JIA-ACR90 | 5/38 (13.2) | 14/43 (32.6) | 16/33 (48.5) | 21/49 (42.9) | |
| Previous biological agent | JIA-ACR70 | 2/23 (8.7) | 32/58 (55.2) | 13/27 (48.1) | 40/55 (72.7) |
| JIA-ACR90 | 2/23 (8.7) | 17/58 (29.3) | 5/27 (18.5) | 32/55 (58.2) | |
*Patients who withdrew or escaped to open-label tocilizumab or for whom the end point could not be determined were classified as non-responders.
†Values are n of N (% of N).
ITT, intent-to-treat; JIA-ACR, juvenile idiopathic arthritis-American College of Rheumatology based on percentage changes of the JIA-CRVs.